Nephrology
| IgA nephropathy
Nephrology
IgA nephropathy

IONIS-FB-LRx – an investigational RNA-targeting therapy: Phase 2 results in IgAN

book_2 Source: Kidney Week 2024. Poster Session.
calendar_today Published on Medfyle: November 2024

In this medfyle

Growing evidence suggests complement activity is an important contributor to IgAN pathology. IONIS-FB-LRx targets Factor B mRNA in the liver, and updated Phase 2 data shared at Kidney Week 2024 support ongoing research into this investigational approach.

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

About this Medfyle
Read more arrow_downward Hide arrow_upward

©2024 Infomedica-Medfyle. All rights reserved.

Source: Phase II Results of an Investigational RNA Therapeutic to Complement Factor B, IONIS-FB-LRx, for Treatment of IgA Nephropathy. Barbour S, et al. Presented at Kidney Week 2024; #TH-PO1205.

The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.


Feedback